Stay updated on IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Sign up to get notified when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.

Latest updates to the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page
- Check2 days agoChange DetectedRevision number updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange Detected- Added the term 'Squamous cell carcinoma of the head and neck' to the study's conditions / MeSH terms to reflect the applicable disease category.SummaryDifference0.1%

- Check23 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 across the site. No changes to study content or functionality are indicated.SummaryDifference0.1%

- Check37 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page was updated to Revision v3.4.2 and the government funding lapse notice was removed; no core trial information, eligibility criteria, or patient-facing content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check73 days agoChange DetectedStatus updated to Active, not recruiting, and results have been posted with key outcomes (ARR, ORR, DCR, PFS). The page now includes linked study documents (Protocol and Statistical Analysis Plan) and updated dates, enrollment, and locations.SummaryDifference4%

Stay in the know with updates to IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.